The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

KEYNOTE-991 trial evaluating Keytruda + Xtandi + androgen deprivation therapy in hormone-sensitive prostate cancer is stopped for futility

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Merck will stop the phase III KEYNOTE-991 trial investigating Keytruda (pembrlizumab), Merck’s anti-PD-1 therapy, in combination with Xtandi (enzalutamide) and androgen deprivation therapy for the treatment of patients with metastatic, hormone-sensitive prostate cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer. 
Clinical Roundup

Blood test predicts prognosis for advanced prostate cancer, study finds

A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account